Advertisement


Andrew Seidman, MD, and Erica Mayer, MD, MPH, on Results of the PALLAS Clinical Trial

2015 San Antonio Breast Cancer Symposium

Advertisement

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Erica L. Mayer, MD, MPH, of the Dana-Farber Cancer Institute, discuss this phase 3 trial of palbociclib with adjuvant endocrine therapy vs endocrine therapy alone for HR-positive/HER2-negative early breast cancer. (Abstract OT1-03-21)



Related Videos

Breast Cancer

Lisa Carey, MD, and Jay Harris, MD, on Critical Decision Making in Radiation Therapy for Breast Cancer

Lisa A. Carey, MD, of the University of North Carolina, and Jay Harris, MD, of Dana-Farber Cancer Institute and Brigham and Women’s Hospital, discuss Dr. Harris' plenary lecture.

Breast Cancer

Lisa Carey, MD, and Kathy Albain, MD, on Results of the SWOG-8814 Trial

Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on adjuvant CAF plus tamoxifen, vs tamoxifen in postmenopausal patients with estrogen receptor–positive, node-positive breast cancer (Abstract S3-02).

Breast Cancer

Jame Abraham, MD, on The JAVELIN and KEYNOTE-028 Study Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).

Breast Cancer
Cost of Care

Benjamin D. Smith, MD, on Mastectomy vs Lumpectomy: Complications and Costs

Benjamin D. Smith, MD, of the MD Anderson Cancer Center, discusses the higher complication rates and economic burdens of mastectomy plus reconstruction vs lumpectomy plus radiation in early breast cancer (Abstract S3-07).

Breast Cancer

Clifford Hudis, MD, and Carlos Arteaga, MD, on Metabolic Syndrome and Obesity in Breast Cancer

Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, adipokines and inflammation, and metformin and lifestyle change in breast cancer and risk for the disease.

Advertisement

Advertisement




Advertisement